The reason this stock can get hammered so easily b
Post# of 153863
(Total Views: 1034)
Posted On: 12/19/2020 3:29:08 AM
The reason this stock can get hammered so easily by shorts is because there are way too many retail investors who know little to nothing about investing, biotech, CytoDyn, SEC filings & rules, and they are just looking to get rich asap with a stock they think they can afford to get some volume in. Too easily manipulated, no resiliency, too emotional, terrified of seeing red and think the sky is falling when they do, because no real due diligence on the science and company has been done.
So, in the interest of educating the easily spooked weak-hands, here’s some insight into the today’s
CytoDyn is putting 2.2 million
company share onto the market as a secondary offering to raise capital through equity. They had these shares on the “shelf” to sell when they need funding. They are being smart about it by offering it when there is a current or upcoming demand for the stock, reflected this week in the market movement with the CD12 trial being filled and results imminent, which will minimize stock dilution, believing that investors will be bullish on buying shares due to the positive market momentum. We all know that CytoDyn naturally has debt as a pre-revenue company, and we were told they need to pay some of it back soon, and they see this is as the best time to do it in a way that doesn’t adversely affect shareholders since there is a lot of interest in the stock due to the pending news and possible catalyst.
The second part of the filing illustrates the conversion of $7.5 million of the recent Fife loan at $3.40 per share. Mike Mulholland stated on the last call that they were satisfyingly the $7.5 million monthly obligation without cash. This keeps $7.5 million in the company bank account, and may help with uplisting because it increases the amount of assets CytoDyn has ($7.5 million cash) that would otherwise be required to be paid back.
We have an honorable and intelligent management team who have a pre-revenue company to find & run, and they value their investors... this timing of the filing reflects that. Don’t fall for any other BS. Things are going in the right direction.
So, in the interest of educating the easily spooked weak-hands, here’s some insight into the today’s
CytoDyn is putting 2.2 million
company share onto the market as a secondary offering to raise capital through equity. They had these shares on the “shelf” to sell when they need funding. They are being smart about it by offering it when there is a current or upcoming demand for the stock, reflected this week in the market movement with the CD12 trial being filled and results imminent, which will minimize stock dilution, believing that investors will be bullish on buying shares due to the positive market momentum. We all know that CytoDyn naturally has debt as a pre-revenue company, and we were told they need to pay some of it back soon, and they see this is as the best time to do it in a way that doesn’t adversely affect shareholders since there is a lot of interest in the stock due to the pending news and possible catalyst.
The second part of the filing illustrates the conversion of $7.5 million of the recent Fife loan at $3.40 per share. Mike Mulholland stated on the last call that they were satisfyingly the $7.5 million monthly obligation without cash. This keeps $7.5 million in the company bank account, and may help with uplisting because it increases the amount of assets CytoDyn has ($7.5 million cash) that would otherwise be required to be paid back.
We have an honorable and intelligent management team who have a pre-revenue company to find & run, and they value their investors... this timing of the filing reflects that. Don’t fall for any other BS. Things are going in the right direction.
(20)
(0)